Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Can-Fite Biopharma Ltd ADR (CANF)

Can-Fite Biopharma Ltd ADR (CANF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,611
  • Shares Outstanding, K 3,540
  • Annual Sales, $ 670 K
  • Annual Income, $ -7,880 K
  • EBIT $ -3 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.11
  • Price/Sales 10.98
  • Price/Cash Flow N/A
  • Price/Book 0.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9900 +3.03%
on 07/01/25
1.1700 -12.82%
on 06/16/25
-0.0750 (-6.85%)
since 06/06/25
3-Month
0.9800 +4.08%
on 05/14/25
1.8200 -43.96%
on 04/14/25
-0.3900 (-27.66%)
since 04/07/25
52-Week
0.9800 +4.08%
on 05/14/25
4.6900 -78.25%
on 07/22/24
-1.4000 (-57.85%)
since 07/05/24

Most Recent Stories

More News
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip...

BIAF : 0.2931 (+7.60%)
CANF : 1.0200 (unch)
Can-Fite BioPharma Reports 8-Year Survival with Namodenoson in Liver Cancer Patient and Announces Phase III Study Enrollment

Can-Fite announces an 8-year complete response in advanced liver cancer patient treated with Namodenoson; Phase III study enrolling now.Quiver AI SummaryCan-Fite BioPharma Ltd. announced promising results...

CANF : 1.0200 (unch)
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) on the...

SXTP : 2.33 (-2.10%)
CANF : 1.0200 (unch)
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New...

CANF : 1.0200 (unch)
Happy Thanksgiving, Uncle Sam!

Monday U.S. Economic Lookahead U.S. leading economic indicators (Oct.) Featured Earnings Agilent ...

A : 119.25 (-1.75%)
NVDA : 158.24 (-0.69%)
DE : 510.29 (-2.05%)
CANF : 1.0200 (unch)
TCOM : 61.46 (+4.63%)
LOW : 224.99 (-1.45%)
KEYS : 162.45 (-2.75%)
GDS : 32.32 (-4.89%)
BMA : 66.38 (-5.17%)
HTHT : 33.95 (+2.17%)
LEXX : 0.8745 (-2.83%)
WN.TO : 271.13 (+0.09%)
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers

MRK : 80.90 (-0.04%)
LLY : 772.87 (-1.00%)
CANF : 1.0200 (unch)
BMY : 46.49 (-0.92%)
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 1.0200 (unch)
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 1.0200 (unch)
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 1.0200 (unch)
Can-Fite Reports 2022 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 1.0200 (unch)

Business Summary

Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate...

See More

Key Turning Points

3rd Resistance Point 1.0800
2nd Resistance Point 1.0600
1st Resistance Point 1.0400
Last Price 1.0200
1st Support Level 1.0000
2nd Support Level 0.9800
3rd Support Level 0.9600

See More

52-Week High 4.6900
Fibonacci 61.8% 3.2728
Fibonacci 50% 2.8350
Fibonacci 38.2% 2.3972
Last Price 1.0200
52-Week Low 0.9800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar